Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 09/12/24 | EFFECT | Notice of Effectiveness |
|
1 | |
| 09/09/24 | S-1 | General form of registration statement for all companies including face-amount certificate companies |
|
   |
137 |
| 09/09/24 | POS AM | Post-effective amendment to a registration statement that is not immediately effective upon filing |
|
3 | |
| 09/09/24 | POS AM | Post-effective amendment to a registration statement that is not immediately effective upon filing |
|
3 | |
| 08/15/24 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
97 |
| 07/22/24 | SC TO-I/A | Issuer tender offer statement |
|
2 | |
| 07/09/24 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
6 | |
| 07/09/24 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
6 | |
| 07/09/24 | SC TO-I/A | Issuer tender offer statement |
|
1 | |
| 07/09/24 | 8-K | Current report filing |
|
|
5 |
